Key Highlights

  • Tempus AI (NASDAQ:TEM) gained 8.67% on November 2, 2026, after third-quarter Revenue rose 23% to USD 411.5 million, slightly above a consensus near USD 409 million.
  • Adjusted EBITDA reached USD 25.6 million, the first positive quarter on that measure, with adjusted Earnings of USD 0.07 a share against an expected loss of USD 0.08.
  • Raised 2026 revenue guidance is USD 1.60 billion to USD 1.605 billion, with adjusted EBITDA guidance held at about USD 65 million.
  • The GAAP net loss for the quarter was USD 14.9 million, according to published coverage, with cash and marketable securities of USD 854.4 million.

What Tempus Reported

Tempus reported third-quarter 2026 results on November 2, 2026. Revenue was USD 411.5 million, up 23%. Diagnostics revenue was USD 303.5 million, up 20%, led by oncology at USD 172.6 million, up 28%, and hereditary testing at USD 111.3 million. Data and applications revenue was USD 108.1 million, up 33%, with data licensing growing 29%. Adjusted EBITDA was USD 25.6 million, which the chief executive described as the turn. The GAAP net loss was USD 14.9 million, according to published coverage. Shares closed up 8.67%, according to published market data. Data and applications made up about 26% of revenue, simple arithmetic, and the two lines sum to the reported total. These figures come from published coverage of the call and release, which could not be matched to the full filing, so treat them as approximate until checked against it.

How the Model Works and What Is Pending

Tempus sells genomic tests to doctors and licenses de-identified clinical and molecular data to drug makers, which use it to design trials. The two lines feed each other: tests add data, and data licensing carries high margins. Published coverage cites a collaboration with a large drug maker worth up to USD 137.5 million over five years and year-to-date data bookings above USD 550 million. Management expects expanded approval for its xT test to add about USD 80 million of average selling price uplift in 2027, a company expectation. A Shareholder vote on the Personalis (NASDAQ:PSNL) Acquisition is scheduled for November 30, 2026. Coverage also mentions a USD 55 million Alzheimer's data initiative and collaborations with several other large drug makers, which show how pharmaceutical Demand feeds the data business.

Risks and What to Watch Next

Profit is still thin. Adjusted EBITDA of USD 25.6 million sits alongside a GAAP loss, and the full-year adjusted EBITDA guidance of about USD 65 million implies the fourth quarter must stay positive. Acquisitions add integration risk, and the pending deal would bring in a Business that must be absorbed. Data revenue depends on a few large pharmaceutical customers. Reimbursement and regulatory decisions for tests are another swing factor. Investors will watch the November 30 vote, fourth-quarter adjusted EBITDA, evidence that unit Economics for residual disease testing improve by mid-2027, and cash use against the USD 854.4 million balance. A failed vote, an adjusted EBITDA miss or slower data bookings would each test the premium the shares now carry.

Where Things Stand

Tempus can hold an 8.7% gain only if it keeps adjusted EBITDA positive and converts data deals into revenue. The quarter delivered 23% growth, a first adjusted profit and a higher revenue forecast, which explains the move. GAAP losses continue, and the Personalis vote adds uncertainty. For Tempus AI (NASDAQ:TEM), the fourth quarter and the November 30 vote are the next catalysts. A single-day gain does not guarantee a trend. Nothing here is Investment advice.